CPT code 80145 represents a laboratory assay that quantifies adalimumab levels in patient specimens. Therapeutic drug monitoring for adalimumab guides clinical management of immune‑mediated diseases treated with this anti–TNF‑alpha biologic and has growing relevance as biologic therapies expand. The code denotes a technical laboratory measurement performed by a lab analyst using immunoassay or similar analytic platforms.

Key payers in the national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how CPT code 80145 is used in clinical care, a summary of payer coverage considerations, and contextual information about clinical applications for adalimumab monitoring. The publication also covers what to expect in billing and service settings, typical sites of service, and common laboratory workflows where this assay is performed.

The report provides benchmarks where available, notes on policy updates affecting lab reimbursement, and clinical context on when adalimumab level testing is ordered. Data not available in the input will be indicated explicitly in relevant sections.